Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.100
+0.030 (2.80%)
At close: May 22, 2026, 4:00 PM EDT
1.110
+0.010 (0.91%)
After-hours: May 22, 2026, 7:54 PM EDT
Quince Therapeutics Employees
Quince Therapeutics had 38 employees as of December 31, 2025. The number of employees increased by 2 or 5.56% compared to the previous year.
Employees
38
Change (1Y)
2
Growth (1Y)
5.56%
Revenue / Employee
n/a
Profits / Employee
-$869,395
Market Cap
17.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 2 | 5.56% | 38 | 0 |
| Dec 31, 2024 | 36 | 4 | 12.50% | 36 | 0 |
| Dec 31, 2023 | 32 | 11 | 52.38% | 32 | 0 |
| Dec 31, 2022 | 21 | -34 | -61.82% | 21 | 0 |
| Dec 31, 2021 | 55 | 17 | 44.74% | 55 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Holdings | 22 |
| IN8bio | 17 |
| NewcelX | 15 |
| Lipocine | 14 |
| Exicure | 8 |
QNCX News
- 7 days ago - UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewsWire
- 7 days ago - Quince Therapeutics Transcript: Investor update - Transcripts
- 7 days ago - Quince Therapeutics Press release: Investor update - Filings
- 7 days ago - Quince Therapeutics Slides: Investor update - Filings
- 7 days ago - Quince Therapeutics announces LAM-001 data - TheFly
- 7 days ago - Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed - TheFly
- 7 days ago - Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - GlobeNewsWire
- 7 days ago - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewsWire